An improved method of encapsulation of doxorubicin in liposomes: Pharmacological, toxicological and therapeutic evaluation

British Journal of Cancer

Volumn 74, Issue 1, 1996, Pages 43-48

  Gokhale, P C ^a   Radhakrishnan, B ^a   Husain, S R ^a   Abernethy, D R ^a   Sacher, R ^a   Dritschilo, A ^a   Rahman, A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiolipin; Doxorubicin; Liposome; Multidrug resistance reversal; Therapeutic efficacy

Indexed keywords

ANTINEOPLASTIC AGENT; CARDIOLIPIN; CHOLESTEROL; DOXORUBICIN; LIPOSOME; PHOSPHATIDYLCHOLINE; VINCRISTINE;

ALOPECIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SCREENING; ENCAPSULATION; FEMALE; HEART; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; LIFESPAN; LIPID COMPOSITION; MALE; MORTALITY; MOUSE; MOUTH ULCER; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030015545     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.313     Document Type: Article

References (33)

1. BIEDLER JL AND RIEHM H. (1970). Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross resistance, radioautographic, and cytogenic studies. Cancer Res., 30, 1174-1184.
2. DANO K. (1973). Active outward transport of daunomycin in resistant Ehrlich ascites tumour cells. Biochim. Biophys. Acta., 323, 466-483.
3. DELGADO G, POTKUL RK, TREAT JA, LEWANDOWSKI GS, BARTER JF, FORST D AND RAHMAN A. (1989). A Phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancers. Am. J. Obstet. Gynecol., 160, 812-819.
4. FORSEN EA AND TOKES ZA. (1981). Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc. Natl Acad. Sci. USA, 78, 1873-1877.
5. FREDERICKSON P, JORGENSON S AND ROESDAHL K. (1974). Activity of Adriamycin in metastatic breast cancer resistant to a combination regimen of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone. Cancer, 33, 519-526.
6. GABIZON A, DAGAN A, GOREN D, BARENHOLZ Y AND FUKS Z. (1982). Liposomes as in vivo carriers of Adriamycin: reduced cardiac uptake and preserved anti-tumour activity in mice. Cancer Res., 42, 4734-4739.
7. GIBALDI M AND PERRIER D. (1982). Pharmacokinetics, 2nd edn, pp. 45-111. Marcel Dekker: New York.
8. GOORMAGHTIGH E AND RUYSSCHAERT JM. (1984). Anthracycline glycoside-membrane interactions. Biochim. Biophys. Acta, 779, 271-288.
9. GOTTESMAN MM AND PASTAN I. (1988). Themultidrug transporter, a double-edged sword. J. Biol. Chem., 263, 12163-12166.
10. GREGORIADIS G, WILLIS EJ, SWAN CP AND TAVILL AS. (1974). Drug carrier potential of liposomes in cancer chemotherapy. Cancer, 1, 1313-1316.
11. HERMAN E, RAHMAN A, FERRANS VJ, VICK JA AND SCHEIN PS. (1983). Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res., 43, 5427-5432.
12. HORIO M, GOTTESMAN MM AND PASTAN I. (1988). ATP-dependent transport of vinblastine in vesicles from human multidrug resistant cells. Proc. Natl Acad. Sci. USA, 85, 3580-3584.
13. JULIANO RL AND LING V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta., 455, 152-162.
14. KARTNER M, EVERNDEN-PORELLE D, BRADLEY G AND LING V. (1985). Detection of p-glycoprotein in multidrug resistance cell lines by monoclonal antibodies. Nature, 316, 820-823.
15. KIM S. (1993). Liposomes as carriers of cancer chemotherapy: current status and future prospects. Drugs, 46, 618-638.
16. McGRATH T AND CENTER MS. (1988). Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res., 48, 3959-3963.
17. MICKISCH G, RAHMAN A, PASTAN I AND GOTTESMAN MM. (1992). Increased effectiveness of liposome encapsulated doxorubicin in multidrug-resistant transgenic mice compared with free doxorubicin. J. Natl Cancer Inst., 84, 804-805.
18. MINOW RA, BENJAMIN RS, LEE ET AND GOTTLIEB JA. (1977). Adriamycin cardiotoxicity-risk factors. Cancer, 39, 1397-1402.
19. MORROW CS AND COWAN KH. (1988). Mechanisms and clinical significance of multidrug resistance. Oncology, 2, 55-67.
20. O'BRYAN RM, BAKER LH, GOTTLIEB JA, RIVKIN SE, BALCERZAK SP, GRUMET GN, SALMON SE, MOON TE AND HOOGSTRATEN B. (1977). Dose response evaluation of Adriamycin in human neoplasia. Cancer, 39, 1940-1948.
21. OLSON F, MAYHEW E, MASLOW D, RUSTUM Y AND SZOKA F. (1982). Characterization, toxicity and therapeutic efficacy of Adriamycin encapsulated in liposomes. Eur. J. Cancer Clin. Oncol., 18, 167-176.
22. OUDARD S, THIERRY A, JORGENSON T AND RAHMAN A. (1991). Sensitization of multidrug resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemorher. Pharmacol., 28, 259-265.
23. RAHMAN A, KESSLER A, MORE N, SIKIC B, ROWDEN G, WOOLLEY PV AND SCHEIN PS. (1980). Liposomal protection of Adriamycin-induced cardiotoxicity in mice. Cancer Res., 40, 1532-1537.
24. RAHMAN A, WHITK G, MORE N AND SCHEIN PS. (1985). Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res., 45, 796-803.
25. RAHMAN A, FUMAGALLI A. BARBIERI B, SCHEIN P AND CASAZZA AM. (1986a). Antitumour and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Chemother. Pharmacol., 16, 22-27.
26. RAHMAN A, GANJEI A AND NEEFE JR. (1986b). Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemother. Pharmacol., 16, 28-34.
27. RAHMAN A, TREAT J, ROE JK, POTKUL LA, ALVORD WG, FORST D AND WOOLLEY PV. (1990). A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J. Clin. Oncol., 8, 1093-1100.
28. RAHMAN A, HUSAIN RS, SIDDIQUI J, VERMA M, AGRESTI M, CENTER M, SAFA A AND GLAZER RJ. (1992). Liposome-mediated modulation of multidrug resistance in human HL-60 leukaemia cells. J. Natl Cancer Inst., 84, 1909-1915.
29. TAN C, ETCUBANAS E, WOLLNER N, ROSEN G, GILLADOGA A, SHOWEL J, MURPHY ML AND KRAKOFF IH. (1973). Adriamycin An antitumour antibiotic in the treatment of neoplastic diseases. Cancer., 32, 9-17.
30. THIERRY AR, JORGENSEN TJ, FORST D, BELLI JA, DRITSCHILO A AND RAHMAN A. (1989). Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Commun., 1, 311-316.
31. THIERRY A, VIGE D, COUGHLIN SS, BELLI JA, DRITSCHILO A AND RAHMAN A. (1993). Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J., 7, 572-579.
32. THIERRY A, RAHMAN A AND DRITSCHILO A. (1994). A new procedure for the preparation of liposomal doxorubicin: biological activity in multidrug-resistant tumour cells. Cancer Chemother. Pharmacol., 35, 84-88.
33. TREAT J, GREENSPAN A, FORST D, SANCHEZ JA, FERRANS VJ, POTKUL LA, WOOLLEY PV AND RAHMAN A. (1990). Antitumour activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J. Natl Cancer Inst., 82, 1706-1710.